Abstract: A responsive microgel is provided which responds volumetrically and reversibly to a change in one or more aqueous conditions selected from the group consisting of (temperature, pH, and ionic conditions) comprised of an ionizable network of covalently cross-linked homopolymeric ionizable monomers wherein the ionizable network is covalently attached to an amphiphilic copolymer to form a plurality of ‘dangling chains’ and wherein the ‘dangling chains’ of amphiphilic copolymer form immobile micelle-like aggregates in aqueous solution. A responsive microgel is further provided that comprises at least one therapeutic entity and delivers a substantially linear and sustained release of the therapeutic entity under physiological conditions.

Abstract: A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituents; R2 represents hydrogen, hydroxy, methoxy or ethoxy; and n represents 0, 1 or 2; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier, provided that the formulation may only contain iota-carrageenan and a neutral gelling polymer when the compound of formula (I) is in the form of a salt; such formulations being of use for the treatment of a cardiovascular disorder

Abstract: The invention is directed to a drug delivery device for controlled release of a drug, comprising a core that has a cylindrical plug embedded therein; and a coating that at least partially surrounds the core. The core is comprised of a drug and excipients. The coating surrounding the core is essentially impermeable to the drug. The cylindrical plug, which is embedded in the core, may be hollow or solid. The drug delivery device enables zero-order drug release profiles as well as more complicated release profiles to be obtained. The invention is also directed to a method of making the drug delivery device.

Abstract: The present invention relates to a colloidal dispersion of amine-terminated silica particles having a narrowly controlled size range in an aqueous phase for use in diagnostic imaging, drug delivery and gene therapy, as well as methods for preparing surface-modified silica particles suitable for use in an aqueous colloidal carrier medium, for preparing a diagnostic or therapeutic agent for targeted delivery to specific anatomical structures of a patient, and for performing a diagnostic or therapeutic procedure by administration to a patient of at least one diagnostic or therapeutic agent coupled with a colloidal dispersion.

Abstract: A method for manufacturing a pharmaceutical composition having uniform drug distribution and potency is described which utilizes silicon dioxide to reduce the loss of active ingredient during the manufacturing process. The method is particularly useful for the manufacture of low dosage tablet compositions.

Abstract: A metal targeting complex which associates with a charged liposomal structure is provided. The metal targeting complex provides the targetability of the liposomal construct to the desired receptor sites of a warm-blooded host for therapy or diagnostic use.

Abstract: The present invention relates to a care and/or make-up composition for the skin and/or lips of human beings, containing a liquid fatty phase comprising at least one anhydrous solvent, structured by a thermotropic liquid crystal polymer in order to obtain media having approximately the consistency of a gel at ambient temperature and that of a fluid when applied to the skin or lips of human beings.

Abstract: Onychomycosis is a fungal infection of the nail bed and is difficult to treat topically because penetration of the nail plate is difficult, and systemic antifungal treatments are prone to side effects and drug interactions. The present invention treats onychomycosis by applying an antifungal composition to the nail bed directly using a solid, semi-solid, or flowable carrier. The carrier can be in the form of a semi-solid into which the user digs and scrapes the nail, a solid carrier can be inserted directly under the nail in contact with the nail bed, or a flowable composition can be injected in contact with the nail bed.

Abstract: The invention relates to amphiphilic, non-ionic oligoesters that are free-flowing at an ambient temperature. Said oligoesters are produced by reacting dicarboxylic acid compounds, polyol compounds of water-soluble alkylene oxide addition products and optionally diol compounds. The invention also relates to detergent formulations and concentrates containing the aforementioned oligoesters and the use of oligoesters as additives in detergents, in particular for cleaning hard surfaces.

Abstract: The present invention provides a polyesteramine, a composition having a polyesteramine according to the present invention as an active ingredient and methods for improving hair detangling, wet and dry combing, shine, gloss, conditioning, surface smoothening, water resistance, film-forming properties, static charge reduction and any combination thereof in various personal care products, such as, hair care, skin care, nail care and cosmetic products. Preferably, the polyesteramine is incorporated into a shampoo, hair conditioner, styling mousse, hair treatment preparation, hair coloring product, semi-perm product, oxidation dye, body wash, liquid soap, skin care preparation, lipstick, mascara, color cosmetic, nail care preparation or any combination thereof.

Abstract: The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.

Abstract: The present invention provides fat-binding polymers, which comprise dialkanolamine, dialkanolammonium, aminoalkylpolyol, and ammoniumalkylpolyol pendant groups for subjects in need of fat removal from the gastrointestinal tract, particularly subjects suffering from steatorrhea and/or experiencing side effects from lipase inhibitors. Patients being administered with lipase inhibitors are typically being treated for Type II Diabetes, streatorrhea, and hypertriglyceridemia. The fat binding polymers of this invention are also suitable for use with obese subjects.

Abstract: A method for manufacturing a pharmaceutical composition having uniform drug distribution and potency is described which utilizes silicon dioxide to reduce the loss of active ingredient during the manufacturing process. The method is particularly useful for the manufacture of low dosage tablet compositions.

Abstract: The present invention is directed to bone replacement devices and compositions containing a synthetic, bioabsorbable, biocompatible liquid polymer that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the liquid polymer having a melting point less than about 40° C., as determined by differential scanning calorimetry.